117 related articles for article (PubMed ID: 5728720)
1. [Differentiation and drug therapy of lipemias].
Schettler G
Dtsch Med J; 1968 Apr; 19(8):250-8. PubMed ID: 5728720
[No Abstract] [Full Text] [Related]
2. The use of lipolytic drugs.
Geill T
Gerontol Clin (Basel); 1965; 7(6):321-9. PubMed ID: 5871676
[No Abstract] [Full Text] [Related]
3. [Differentiation and drug therapy of lipemias].
Schettler G
Clin Ter; 1968 Jun; 44(6):513-32. PubMed ID: 5736872
[No Abstract] [Full Text] [Related]
4. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
[No Abstract] [Full Text] [Related]
5. [Differentiation of essential familial hyperlipoproteinemias (hyperlipemias)].
Kahlke W
Dtsch Med Wochenschr; 1966 Jan; 91(1):26-9. PubMed ID: 5901099
[No Abstract] [Full Text] [Related]
6. [Importance of the clofibrat in the treatment of lipid metabolism disorders].
Laubinger G
Med Klin; 1968 Jan; 63(4):139-42. PubMed ID: 5670163
[No Abstract] [Full Text] [Related]
7. [The therapeutic use of CPIB in pathological increase of the lipid constituents of the blood].
Cloarec M; Cottet J; Etienne J; Loeper J
Sem Ther; 1965 Nov; 41(9):499-500. PubMed ID: 5877602
[No Abstract] [Full Text] [Related]
8. Clofibrate and androsterone effect on serum lipids.
Orgain ES; Bogdonoff MD; Cain C
Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838
[No Abstract] [Full Text] [Related]
9. [Unorthodox reflections about arteriosclerosis].
Kaunitz H
Wien Klin Wochenschr; 1970 Nov; 82(46):825-8. PubMed ID: 5521420
[No Abstract] [Full Text] [Related]
10. [Changes of the coefficient of peripheral utilization of glucose after venous administration, in hypercholesteremic subjects, after treatment with an antidyslipidemic agent].
Pasini P
G Gerontol; 1969 Aug; 17(8):808-16. PubMed ID: 5371744
[No Abstract] [Full Text] [Related]
11. [Action of aluminum bis-parachlorophenoxyisobutyrate (2CPIBA) on various hyperlipoproteinemias: initial results].
Vastesaeger MM; Peeters H; Blaton V; Vanderveiken F; Vastesaeger E
Brux Med; 1969 Oct; 49(10):615-29. PubMed ID: 5402903
[No Abstract] [Full Text] [Related]
12. [Diagnosis and therapy of lipid metabolism disorders].
Eberhardt G
Offentl Gesundheitswes; 1971 Oct; 33(10):633-41. PubMed ID: 4259373
[No Abstract] [Full Text] [Related]
13. [Differentiation and drug therapy of lipemias].
Schettler G
Folia Clin Int (Barc); 1969 Apr; 19(4):205-22. PubMed ID: 5397578
[No Abstract] [Full Text] [Related]
14. [A case of essential hyperlipemia treated with atromid].
Baczko A; Ciświcka-Sznajderman M; Jakubowicz K; Sznajderman M
Kardiol Pol; 1965; 8(2):135-41. PubMed ID: 5836657
[No Abstract] [Full Text] [Related]
15. Diagnosis and treatment of hypercholesterolemia and hypertriglyceridemia.
Scheig R
Conn Med; 1975 Feb; 39(2):71-3. PubMed ID: 1109860
[No Abstract] [Full Text] [Related]
16. [Action of ethyl chlorophenoxyisobutyrate on several types of hyperlipidemia].
Beaumont V; Swynghedauw B; Beaumont JL; Himbert J
Rev Atheroscler (Paris); 1966; 8(1):12-20. PubMed ID: 5961026
[No Abstract] [Full Text] [Related]
17. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
Fodor JG; Frohlich JJ; Genest JJ; McPherson PR
CMAJ; 2000 May; 162(10):1441-7. PubMed ID: 10834048
[No Abstract] [Full Text] [Related]
18. Diagnosis and treatment of Type II and Type IV hyperlipoproteinemia in the office practice setting.
Millett F; Sielski J; Stoll H; Alston N; Gail S
PA J; 1976; 6(2):54-9. PubMed ID: 10235781
[No Abstract] [Full Text] [Related]
19. [Treatment of hyperlipidemia].
Oye I
Tidsskr Nor Laegeforen; 1973 Jan; 93(1):31-2. PubMed ID: 4691221
[No Abstract] [Full Text] [Related]
20. Hyperlipidemia - a diabetic emergency.
Saudek CD
Geriatrics; 1982 Feb; 37(2):81-9. PubMed ID: 7056473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
